

KING PHARMACEUTICALS INC

Form 8-K

November 07, 2006

**Table of Contents**

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549  
FORM 8-K  
CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): November 7, 2006 (November 1, 2006)

**King Pharmaceuticals, Inc.**

(Exact name of registrant as specified in charter)

Tennessee

001-15875

54-1684963

(State or other jurisdiction  
of incorporation)

(Commission  
File Number)

(I.R.S. Employer  
Identification No.)

501 Fifth Street, Bristol, Tennessee

37620

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code: (423) 989-8000

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**TABLE OF CONTENTS**

Item 2.05 Costs Associated with Exit or Disposal Activities.

Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.

Item 9.01 Financial Statements and Exhibits.

**SIGNATURES**

**EXHIBIT INDEX**

Ex-99.1 November 7, 2006 Press Release

---

**Table of Contents**

**Item 2.05 Costs Associated with Exit or Disposal Activities.**

On November 1, 2006, the board of directors of King approved a plan to close King's St. Petersburg, Florida facility in connection with the transfer of production of Levoxy1® from the St. Petersburg facility to King's Bristol, Tennessee facility, which King expects to be completed by the end of 2008. As a result of this decision, King expects to incur restructuring charges over this period of time of approximately \$11,000,000, including approximately \$6,000,000 related to non-cash accelerated depreciation and approximately \$5,000,000 for associated cash employee termination payments.

**Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.**

On November 1, 2006, the board of directors of King appointed Philip A. Incarnati to King's board of directors to serve as a Class III director. Mr. Incarnati will serve on the board's audit committee.

Mr. Incarnati is not a party to any arrangement or understanding with any person pursuant to which Mr. Incarnati was elected as a director, nor is Mr. Incarnati a party to any transaction, or series of transactions, required to be disclosed pursuant to Item 404(a) of Regulation S-K.

A copy of the press release announcing Mr. Incarnati's appointment to the board of directors is included herewith as Exhibit 99.1.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

99.1 Press release of King Pharmaceuticals, Inc. dated November 7, 2006.

---

**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 7, 2006

KING PHARMACEUTICALS, INC.

By: /s/ Joseph Squicciarino  
Joseph Squicciarino  
Chief Financial Officer

---

**Table of Contents**

**EXHIBIT INDEX**

**Exhibit**

**No.**

**Description**

99.1

Press release of King Pharmaceuticals, Inc. dated November 7, 2006.